Listen on the go
CORRECT!
Next question
touchRESPIRATORY touchRESPIRATORY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Dietetic intervention in malnourished patients with interstitial lung disease
JOURNALS
Start Learning
GINA 2024: Key Updates to optimise asthma care standards
touchFOCUS
Start Learning
Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
CE/CME ACCREDITED
touchPANEL DISCUSSION
Start Learning
Expanding HER2 horizons: Implications for NSCLC and beyond
CE/CME ACCREDITED
touchMDT
Start Learning
Precision targeting of MET in NSCLC: A multidisciplinary approach
CE/CME ACCREDITED
JOURNALS
Start Learning
Dupilumab gains first-in-world approval for treating COPD with elevated blood eosinophils
touchMDT
Start Learning
Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
CE/CME ACCREDITED
touchEXPERT OPINIONS
Start Learning
Optimizing management of bronchiolitis obliterans syndrome: Current strategies, future directions
CE/CME ACCREDITED
touchIN CONVERSATION
Start Learning
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
CE/CME ACCREDITED
touchCLINICAL PERSPECTIVES
Start Learning
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Roflumilast Role in the Prevention of Acute Exacerbation in Chronic Obstructive Pulmonary Disease: A Narrative Review
View
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
View
Reflecting on 2024 and looking ahead to 2025: A message from Dr Xander Bertels, New Patient Advisory Board & Advocacy Manager, EUFOREA
View
New treatment for eosinophilic asthma and COPD exacerbations shows potential
View
Asthma Right Care: Aiming to improve asthma management globally
View
GINA 2024: Key Updates to optimise asthma care standards
View
Precision targeting of MET in NSCLC: A multidisciplinary approach
View
Current treatments and unmet needs in limited-stage small cell lung cancer
View
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
View
Foreword – touchREVIEWS in Respiratory & Pulmonary Diseases, Volume 9, Issue 1, 2024
View
In Partnership with...
Useful Links:
About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
Connect With Us:

Other websites from Touch Medical Media:

touchONCOLOGY
touchOPHTHALMOLOGY
touchENDOCRINOLOGY
touchNEUROLOGY
touchCARDIO
touchRESPIRATORY
touchIMMUNOLOGY
touchINFECTIOUS DISEASES
touchHAEMATOLOGY
touchDERMATOLOGY

Copyright® 2025 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

touchRESPIRATORY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup